Pliant Therapeutics Inc
(NAS:PLRX)
$
10.71
-0.49 (-4.38%)
Market Cap: 646.09 Mil
Enterprise Value: 218.36 Mil
PE Ratio: 0
PB Ratio: 1.48
GF Score: 34/100 - Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call TranscriptFeb 05, 2024
- Pliant Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Pliant Therapeutics Inc INTEGRIS-PSC Interim Phase 2a Data Presentation TranscriptSep 26, 2023
- Pliant Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Pliant Therapeutics Inc INTEGRIS-IPF Call TranscriptMay 01, 2023
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Pliant Therapeutics Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Pliant Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call TranscriptJan 23, 2023
- Pliant Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Pliant Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) TranscriptOct 07, 2022
- Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call TranscriptJul 11, 2022
- Pliant Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 18, 2022
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 05:35PM GMT
Release Date Price:
$21.53
(-3.02%)
Brian Abrahams
RBC Capital Markets - Analyst
I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our next presenting company is Pliant Therapeutics. I'm very pleased to have their CFO, Keith Cummings; and their Chief Medical Officer, Ãric Lefebvre. So Keith and Eric, thanks again.
Ã;ric Lefebvre
Pliant Therapeutics, Inc. - Chief Medical Officer
Thank you.
Keith Cummings
Pliant Therapeutics, Inc. - CFO
Thank you.
Questions & Answers
Brian Abrahams
RBC Capital Markets - Analyst
So maybe just kicking things off, you guys recently presented some updated data for bexo and your Phase 2 IPF study. Can you maybe just run us through the key highlights from that data, maybe the Phase 2 overall and then the six-month data at the 320-mg dose that I think has been the most recent data you have talked about.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)